Home › Research › Inflammation and the immune system
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts
Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA et al.. Journal of neural transmission (Vienna, Austria : 1996), 1998-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Many approaches have been undertaken to understand Alzheimer's disease (AD) but the heterogeneity of the etiologic factors makes it difficult to define the clinically most important factor determining the onset and progression of the disease. However, there is increasing evidence that the previously so-called "secondary factors" such as a disturbed glucose metabolism, oxidative stress and formation of "advanced glycation endproducts" (AGEs) and their interaction in a vicious cycle are also important for the onset and progression of AD. AGEs are protein modifications that contribute to the formation of the histopathological and biochemical hallmarks of AD: amyloid plaques, neurofibrillary tangles and activated microglia.
What this study adds
Evidence grade: Low
This is a narrative review. This paper proposes that disturbed glucose metabolism, oxidative stress and advanced glycation endproducts interact in a vicious cycle that contributes to the onset and progression of Alzheimer's disease. It is a review of evidence rather than a clinical trial, so it does not show that targeting these factors treats or prevents the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Münch, G., Schinzel, R., Loske, C., Wong, A., Durany, N., Li, J. J., et al. (1998). Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of neural transmission (Vienna, Austria : 1996). https://doi.org/10.1007/s007020050069
Vancouver
Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, et al. Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of neural transmission (Vienna, Austria : 1996). 1998. doi:10.1007/s007020050069. PMID: 9720973.
BibTeX
@article{munch1998-9720973,
author = {Münch, G. and Schinzel, R. and Loske, C. and Wong, A. and Durany, N. and Li, J. J. and Vlassara, H. and Smith, M. A. and others},
title = {{Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts}},
journal = {Journal of neural transmission (Vienna, Austria : 1996)},
year = {1998},
doi = {10.1007/s007020050069},
pmid = {9720973},
url = {https://doi.org/10.1007/s007020050069}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, there is increasing evidence that the previously so-called "secondary factors" such as a disturbed glucose metabolism, oxidative stress and formation of "advanced glycation endproducts" (AGEs) and their interaction in a vicious cycle are also important for the onset and progression of AD.
- AGEs are protein modifications that contribute to the formation of the histopathological and biochemical hallmarks of AD: amyloid plaques, neurofibrillary tangles and activated microglia.
- Oxidative modifications are formed by a complex cascade of dehydration, oxidation and cyclisation reactions, subsequent to a non-enzymatic reaction of sugars with amino groups of proteins.
- Accumulation of AGE-crosslinked proteins throughout life is a general phenomenon of ageing.
Why it matters
This paper proposes that disturbed glucose metabolism, oxidative stress and advanced glycation endproducts interact in a vicious cycle that contributes to the onset and progression of Alzheimer's disease. It is a review of evidence rather than a clinical trial, so it does not show that targeting these factors treats or prevents the disease.
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neural transmission (Vienna, Austria : 1996)) |
| Journal's citation record | 2 / 4 | Journal of Neural Transmission: journal h-index 167 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1998 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 304 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.1 citations a year over 30 year(s) since 1998 |
| Impact for its field and year | 4 / 6 | Cited 9.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 13 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Peter Franz Riederer: h-index 108 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Case Western Reserve University: institution h-index 1,159 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 9720973) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Inflammation and the immune system from nearby years
Also in Inflammation and the immune system
138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.